The first platform technology for direct, sensitive detection and quantification of DNA breaks at the individual lesion level. Unlike conventional methods dependent on complex DDR signaling, STRIDE® provides proximal, quantifiable readouts with single-lesion sensitivity.
Breakthrough technology enabling direct DNA damage detection without reliance on cellular signaling pathways.
Detect and quantify DNA breaks at the individual lesion level—no reliance on complex DDR signaling pathways.
Validate targets and mechanism-of-action studies with direct, quantifiable readouts.
Develop pharmacodynamic biomarkers for clinical trials with unprecedented precision.
Functional analysis of HR, MMR, and BER pathways with visual evidence.
STRIDE® runs natively on the BioCompute platform, ensuring your DNA damage data flows seamlessly through our Evidence Engine with full regulatory compliance.
STRIDE® Workflow
Integrated Analysis Pipeline
Sample Ingestion
Single-cell resolution data capture
STRIDE® Analysis
DNA break quantification
Evidence Generation
Audit-ready visual reports
Regulatory Export
FDA 21 CFR Part 11 compliant
How leading pharma and biotech companies leverage STRIDE® on BioCompute.
faster target validation
Validate DDR-targeting compounds with single-molecule precision. Fail fast on ineffective candidates before costly clinical trials.
Part 11 compliant
Quantify DNA damage from radiolabeled compounds with audit-ready evidence for IND submissions.
traceability
Assess off-target effects and genotoxicity with visual evidence at single-cell resolution.